23andMe Holding Co. (ME) Operating Margin: -114.00%
Is 23andMe Holding Co.’s operating margin high or low?
23andMe Holding Co.'s operating margin of -114.00% is 10% below its 5-year average of -103.43%, around the middle of its 5-year range (-146.31%–-69.98%).
As of Saturday, June 20, 2026. 16.49% above its 12-month average of -136.51%.
ME Operating Margin Chart
ME Average Operating Margin Chart
ME Current vs Average Operating Margin Chart
ME Operating Margin Metrics
OPERATING MARGIN
-114.00%
OPERATING MARGIN AVG TTM
-136.51%
OPERATING MARGIN AVG 3Y
-118.68%
OPERATING MARGIN AVG 5Y
-103.43%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+16.49%
CURRENT VS 3Y AVG
+3.94%
CURRENT VS 5Y AVG
-10.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -114.00% | -136.51% | -118.68% | -103.43% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 5.87% | -8.16% | -10.59% | -4.68% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 14.85% | 13.21% | -4.78% | -42.05% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 9.25% | 10.48% | 12.70% | 14.08% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 1.32% | 4.35% | -1.93% | -10.04% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -18.13% | -59.22% | -59.52% | -72.58% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 11.77% | 9.13% | 12.39% | 13.51% |
| Baxter International Inc. (BAX)vs › | $10.27B | -2.65% | -1.31% | -6.02% | 0.15% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -2.02% | -7.24% | -2.92% | -1.15% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 12.41% | 13.70% | 16.38% | 21.25% |
Operating Efficiency
Gross Margin
53.3%
Operating Margin
-114.0%
23andMe Holding Co. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Operating Margin FAQ
- What is the operating margin for 23andMe Holding Co. (ME)?
- The operating margin for ME stock is -114.00%.
- Is 23andMe Holding Co.'s operating margin high or low?
- 23andMe Holding Co.'s operating margin of -114.00% is 10% below its 5-year average of -103.43%, around the middle of its 5-year range (-146.31%–-69.98%).
- What is the TTM average operating margin for 23andMe Holding Co. (ME)?
- The TTM average operating margin for ME stock is -136.51%.
- What is the 3Y average operating margin for 23andMe Holding Co. (ME)?
- The 3Y average operating margin for ME stock is -118.68%.
- What is the 5Y average operating margin for 23andMe Holding Co. (ME)?
- The 5Y average operating margin for ME stock is -103.43%.
23andMe Holding Co. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-03-31 | -126.72% |
| 2024-03-31 | -146.31% |
| 2023-03-31 | -108.19% |
| 2022-03-31 | -93.48% |
| 2021-03-31 | -75.92% |
| 2020-03-31 | -69.98% |
| 2019-03-31 | -42.82% |
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage